Free Trial

Atossa Therapeutics (ATOS) News Today

Atossa Therapeutics logo
$0.66 -0.03 (-4.16%)
As of 12:46 PM Eastern
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday
Atossa Therapeutics (NASDAQ:ATOS) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.
Atossa Therapeutics, Inc. stock logo
Q1 EPS Forecast for Atossa Therapeutics Boosted by Analyst
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for Atossa Therapeutics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings o
Q1 EPS Forecast for Atossa Therapeutics Lifted by Analyst
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.
Atossa Therapeutics reports Q4 EPS (20c), consensus (22c)
Q4 2024 Atossa Therapeutics Inc Earnings Call
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (ATOS) to Release Earnings on Tuesday
Atossa Therapeutics (NASDAQ:ATOS) will be releasing earnings on Tuesday, March 25, Financial Modeling Prep reports.
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (NASDAQ:ATOS) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Significant Growth in Short Interest
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 9,250,000 shares, an increase of 5.8% from the January 15th total of 8,740,000 shares. Based on an average daily volume of 876,500 shares, the days-to-cover ratio is presently 10.6 days.
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving Average - Here's Why
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Below 200-Day Moving Average - Here's Why
Atossa Therapeutics, Inc. stock logo
What is HC Wainwright's Estimate for ATOS FY2029 Earnings?
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Atossa Therapeutics in a research report issued to clients and investors on Thursday, January 30th. HC Wainwright analyst E. Bodnar expects that the co
Atossa Therapeutics, Inc. stock logo
Equities Analysts Set Expectations for ATOS FY2029 Earnings
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Atossa Therapeutics in a report released on Thursday, January 30th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.14) per share fo
Atossa Therapeutics, Inc. stock logo
HC Wainwright Reiterates "Buy" Rating for Atossa Therapeutics (NASDAQ:ATOS)
HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Thursday.
Seattle Doctor: Quit Drinking Now
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Sees Large Decrease in Short Interest
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a drop of 29.3% from the November 30th total of 11,600,000 shares. Based on an average daily volume of 705,500 shares, the short-interest ratio is currently 11.6 days.
Atossa Therapeutics, Inc. stock logo
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Down 6.8% in November
Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) saw a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 11,600,000 shares, a decline of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily volume of 628,500 shares, the days-to-cover ratio is presently 18.5 days.
Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study
Atossa Therapeutics announces three posters on Phase 2 EVANGELINE trial
Remove Ads
Get Atossa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

ATOS Media Mentions By Week

ATOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATOS
News Sentiment

0.54

0.57

Average
Medical
News Sentiment

ATOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATOS Articles
This Week

9

2

ATOS Articles
Average Week

Remove Ads
Get Atossa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ATOS) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners